Berliner Boersenzeitung - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.211393
AFN 72.244796
ALL 95.982096
AMD 432.319357
ANG 2.052753
AOA 1051.557417
ARS 1603.424201
AUD 1.641243
AWG 2.064125
AZN 1.954004
BAM 1.955435
BBD 2.309469
BDT 140.703754
BGN 1.960126
BHD 0.435819
BIF 3404.065016
BMD 1.146736
BND 1.467326
BOB 7.923522
BRL 6.112796
BSD 1.146686
BTN 105.842257
BWP 15.625085
BYN 3.392867
BYR 22476.027392
BZD 2.30607
CAD 1.583471
CDF 2588.183773
CHF 0.912745
CLF 0.026638
CLP 1051.798264
CNY 7.908585
CNH 7.921286
COP 4222.512346
CRC 539.499363
CUC 1.146736
CUP 30.388506
CVE 110.244435
CZK 24.575006
DJF 204.191911
DKK 7.505507
DOP 70.446859
DZD 153.116438
EGP 59.873831
ERN 17.201041
ETB 178.984913
FJD 2.555735
FKP 0.866182
GBP 0.866311
GEL 3.131037
GGP 0.866182
GHS 12.452677
GIP 0.866182
GMD 84.289519
GNF 10052.124908
GTQ 8.79336
GYD 239.895251
HKD 8.97946
HNL 30.352338
HRK 7.568004
HTG 150.351954
HUF 394.179508
IDR 19448.701448
ILS 3.605729
IMP 0.866182
INR 106.170389
IQD 1502.119799
IRR 1515669.760861
ISK 144.837141
JEP 0.866182
JMD 179.916439
JOD 0.813081
JPY 183.185402
KES 148.312334
KGS 100.281732
KHR 4598.142277
KMF 494.243657
KPW 1032.019272
KRW 1723.258101
KWD 0.352542
KYD 0.955522
KZT 561.355287
LAK 24570.416711
LBP 102681.246162
LKR 356.863432
LRD 209.830859
LSL 19.258608
LTL 3.386014
LVL 0.69365
LYD 7.316635
MAD 10.799685
MDL 20.003269
MGA 4761.111877
MKD 61.628504
MMK 2408.293814
MNT 4109.908675
MOP 9.243576
MRU 45.877442
MUR 53.33513
MVR 17.717506
MWK 1988.229122
MXN 20.584147
MYR 4.516425
MZN 73.288336
NAD 19.258608
NGN 1588.807126
NIO 42.19213
NOK 11.176343
NPR 169.34741
NZD 1.985003
OMR 0.440925
PAB 1.146586
PEN 3.954262
PGK 5.014065
PHP 68.334433
PKR 320.169477
PLN 4.298483
PYG 7397.620071
QAR 4.168222
RON 5.117429
RSD 117.34811
RUB 91.632507
RWF 1673.28787
SAR 4.303626
SBD 9.233195
SCR 17.507734
SDG 689.18878
SEK 10.871865
SGD 1.469547
SHP 0.860349
SLE 28.152796
SLL 24046.494883
SOS 654.177972
SRD 43.05769
STD 23735.121842
STN 24.495431
SVC 10.033128
SYP 126.777699
SZL 19.252409
THB 37.071728
TJS 10.99055
TMT 4.013576
TND 3.391067
TOP 2.761065
TRY 50.645643
TTD 7.776549
TWD 36.918714
TZS 2986.942825
UAH 50.565468
UGX 4311.195803
USD 1.146736
UYU 46.061408
UZS 13845.417319
VES 507.665371
VND 30152.278788
VUV 137.132233
WST 3.13652
XAF 655.834663
XAG 0.014239
XAU 0.000228
XCD 3.099112
XCG 2.066515
XDR 0.815648
XOF 655.834663
XPF 119.331742
YER 273.554311
ZAR 19.360243
ZMK 10322.005017
ZMW 22.318837
ZWL 369.248554
  • RBGPF

    0.1000

    82.5

    +0.12%

  • CMSD

    -0.1100

    22.99

    -0.48%

  • JRI

    -0.2300

    12.59

    -1.83%

  • NGG

    0.0900

    90.9

    +0.1%

  • AZN

    -2.6000

    189.9

    -1.37%

  • BCE

    -0.1100

    25.57

    -0.43%

  • GSK

    -0.8900

    53.39

    -1.67%

  • BCC

    0.3800

    70

    +0.54%

  • RIO

    -2.8700

    87.83

    -3.27%

  • RELX

    -0.0400

    34.14

    -0.12%

  • CMSC

    -0.1500

    22.99

    -0.65%

  • BTI

    0.0400

    59.93

    +0.07%

  • VOD

    0.1000

    14.41

    +0.69%

  • RYCEF

    -1.1300

    16.12

    -7.01%

  • BP

    0.5100

    42.67

    +1.2%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

(G.Gruner--BBZ)